Teva Stock Has Risen Significantly since November Lows: What’s Next?
Teva Pharmaceuticals released its 3Q17 earnings results on November 2, 2017. The disappointing earnings and the company’s lowering of its fiscal 2017 guidance triggered negative investor sentiments, which led to a massive decline of approximately 20% in TEVA stock prices. The company has run into troubles over the past year and it reported a dismal performance in 3Q17. For details, read, Inside Teva’s 3Q17 Performance.